Shengwu Liu

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan et al. · Nature Medicine · 2018 · 443 citations · Full text

Tumor Biology, Oncology, Kinase Inhibitor +12

Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4

Xiangpeng Dai, Wenjian Gan, Xiaoning Li et al. · Nature Medicine · 2017 · 333 citations · Full text

Molecular Biology, Bet Inhibitors, Spop Mutations +6

T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling

Man Li, Pengyan Xia, Ying Du et al. · Journal of Biological Chemistry · 2014 · 244 citations · Full text

Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Francois Gonzalvez, Sylvie Vincent, Theresa E. Baker et al. · Cancer Discovery · 2021 · 188 citations · Full text

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer

Dennis O. Adeegbe, Yan Liu, Patrick H. Lizotte et al. · Cancer Discovery · 2017 · 145 citations · Full text